Childhood thyroid cancers and radioactive iodine therapy: Necessity of precautious radiation health risk management

Endocrine Journal

Volumn 54, Issue 6, 2007, Pages 839-847

  Kumagai, Atsushi ^a,b   Reiners, Christoph ^c   Drozd, Valentina ^d   Yamashita, Shunichi ^a,b  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^b WORLD HEALTH ORGANIZATION   (Switzerland)

^c UNIVERSITY OF WÜRZBURG   (Germany)

^d Clin Inst of Rad Med Endocr   (Belarus)

Author keywords

Chernobyl nuclear disaster; Radiation induced childhood thyroid cancer; Radioactive iodine therapy; Radiological protection; Second cancer risk

Indexed keywords

AMIFOSTINE; B RAF KINASE; IODINE; IODINE 131; RECOMBINANT HORMONE; TEMPOL; THYROTROPIN;

AGEUSIA; ALLERGIC REACTION; CANCER RADIOTHERAPY; CANCER RISK; FOLLOW UP; GENE MUTATION; HUMAN; HYPOTENSION; NAUSEA; REVIEW; SALIVARY GLAND CANCER; SIALOADENITIS; THYROID CANCER; VOMITING; XEROSTOMIA;

ADOLESCENT; ADULT; CHILD; FEMALE; HUMANS; IODINE RADIOISOTOPES; MALE; NEOPLASMS, RADIATION-INDUCED; NEOPLASMS, SECOND PRIMARY; RISK ASSESSMENT; THYROID NEOPLASMS; THYROTROPIN; THYROXINE;

EID: 40449084347     PISSN: 09188959     EISSN: 13484540     Source Type: Journal    
DOI: 10.1507/endocrj.K07E-012     Document Type: Review

References (70)

1. World Health Organization: Ionizing radiation, Health effects of the Chernobyl accident. http://www.who.int/ionizing_radiation/chernobyl/en/
2. Bennett B, Repacholi M, Carr Z (2006) Health Effects of the Chernobyl Accident and Special Health Care Programmes. World Health Organaization. http://www.who.int/ionizing_radiation/chernobyl/who_chernobyl_report_2006.pdf
3. The Chernobyl Forum Chernobyl's Legacy: Health, Environmental and Socio-Economic Impacts and Recommendations to the Governments of Belarus, the Russian Federation and Ukraine. The Chernobyl Forum: 2003-2005. http://www.iaea.org/Publications/Booklets/Chernobyl/chernobyl.pdf
4. Demidchik YE, Demidchik EP, Reiners C, Biko J, Mine M, Saenko VA, Yamashita S (2006) Comprehensive clinical assessment of 740 cases of surgically treated thyroid cancer in children of Belarus. Ann Surg 243: 525-532.
5. Demidchik YE, Demidchik EP, Saenko VA, Reiners C, Biko J, Mankovskaya SV, Yamashita S (2007) Childhood thyroid cancer in Belarus. In: Shibata Y, Namba H, Suzuki K, Tomonaga M (eds) Radiation Risk Perspectives First ed. ELSEVIER B.V., Amsterdam, vol 1299: 32-38.
6. Ron E, Lubin JH, Shore RE, Mabuchi K, Modan B, Pottern LM, Schneider AB, Tucker MA, Boice JD Jr (1995) Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. Radiat Res 141: 259-277.
7. Preston DL, Shimizu Y, Pierce DA, Suyama A, Mabuchi K (2003) Studies of mortality of atomic bomb survivors. Report 13: Solid cancer and noncancer disease mortality: 1950-1997. Radiat Res 160: 381-407.
8. Imaizumi M, Usa T, Tominaga T, Neriishi K, Akahoshi M, Nakashima E, Ashizawa K, Hida A, Soda M, Fujiwara S, Yamada M, Ejima E, Yokoyama N, Okubo M, Sugino K, Suzuki G, Maeda R, Nagataki S, Eguchi K (2006) Radiation dose-response relationships for thyroid nodules and autoimmune thyroid diseases in Hiroshima and Nagasaki atomic bomb survivors 55-58 years after radiation exposure. Jama 295: 1011-1022.
9. Travis LB, Gospodarowicz M, Curtis RE, Clarke EA, Andersson M, Glimelius B, Joensuu T, Lynch CF, van Leeuwen FE, Holowaty E, Storm H, Glimelius I, Pukkala E, Stovall M, Fraumeni JF Jr, Boice JD Jr, Gilbert E (2002) Lung cancer following chemotherapy and radiotherapy for Hodgkin's disease. J Natl Cancer Inst 94: 182-192.
10. Dores GM, Metayer C, Curtis RE, Lynch CF, Clarke EA, Glimelius B, Storm H, Pukkala E, van Leeuwen FE, Holowaty EJ, Andersson M, Wiklund T, Joensuu T, van't Veer MB, Stovall M, Gospodarowicz M, Travis LB (2002) Second malignant neoplasms among long-term survivors of Hodgkin's disease: a population-based evaluation over 25 years. J Clin Oncol 20: 3484-3494.
11. van Leeuwen FE, Klokman WJ, Stovall M, Dahler EC, van't Veer MB, Noordijk EM, Crommelin MA, Aleman BM, Broeks A, Gospodarowicz M, Travis LB, Russell NS (2003) Roles of radiation dose, chemotherapy, and hormonal factors in breast cancer following Hodgkin's disease. J Natl Cancer Inst 95: 971-980.
12. Travis LB, Hill DA, Dores GM, Gospodarowicz M, van Leeuwen FE, Holowaty E, Glimelius B, Andersson M, Wiklund T, Lynch CF, Van't Veer MB, Glimelius I, Storm H, Pukkala E, Stovall M, Curtis R, Boice JD Jr, Gilbert E (2003) Breast cancer following radiotherapy and chemotherapy among young women with Hodgkin disease. Jama 290: 465-475.
13. Travis LB, Hill D, Dores GM, Gospodarowicz M, van Leeuwen FE, Holowaty E, Glimelius B, Andersson M, Pukkala E, Lynch CF, Pee D, Smith SA, Van't Veer MB, Joensuu T, Storm H, Stovall M, Boice JD Jr, Gilbert E, Gail MH (2005) Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma. J Natl Cancer Inst 97: 1428-1437.
14. Dottorini ME, Vignati A, Mazzucchelli L, Lomuscio G, Colombo L (1997) Differentiated thyroid carcinoma in children and adolescents: a 37-year experience in 85 patients. J Nucl Med 38: 669-675.
15. Rubino C, de Vathaire F, Dottorini ME, Hall P, Schvartz C, Couette JE, Dondon MG, Abbas MT, Langlois C, Schlumberger M (2003) Second primary malignancies in thyroid cancer patients. Br J Cancer 89: 1638-1644.
16. Behrens C, Travis LB, Wistuba, II, Davis S, Maitra A, Clarke EA, Lynch CF, Glimelius B, Wiklund T, Tarone R, Gazdar AF (2000) Molecular changes in second primary lung and breast cancers after therapy for Hodgkin's disease. Cancer Epidemiol Biomarkers Prev 9: 1027-1035.
17. Metayer C, Lynch CF, Clarke EA, Glimelius B, Storm H, Pukkala E, Joensuu T, van Leeuwen FE, van't Veer MB, Curtis RE, Holowaty EJ, Andersson M, Wiklund T, Gospodarowicz M, Travis LB (2000) Second cancers among long-term survivors of Hodgkin's disease diagnosed in childhood and adolescence. J Clin Oncol 18: 2435-2443.
18. de Vathaire F, Hardiman C, Shamsaldin A, Campbell S, Grimaud E, Hawkins M, Raquin M, Oberlin O, Diallo I, Zucker JM, Panis X, Lagrange JL, Daly-Schveitzer N, Lemerle J, Chavaudra J, Schlumberger M, Bonaiti C (1999) Thyroid carcinomas after irradiation for a first cancer during childhood. Arch Intern Med 159: 2713-2719.
19. Rubino C, Adjadj E, Guerin S, Guibout C, Shamsaldin A, Dondon MG, Valteau-Couanet D, Hartmann O, Hawkins M, de Vathaire F (2003) Long-term risk of second malignant neoplasms after neuroblastoma in childhood: role of treatment. Int J Cancer 107: 791-796.
20. Wong FL, Boice JD Jr, Abramson DH, Tarone RE, Kleinerman RA, Stovall M, Goldman MB, Seddon JM, Tarbell N, Fraumeni JF Jr, Li FP (1997) Cancer incidence after retinoblastoma. Radiation dose and sarcoma risk. Jama 278: 1262-1267.
21. Rubino C, de Vathaire F, Shamsaldin A, Labbe M, Le MG (2003) Radiation dose, chemotherapy, hormonal treatment and risk of second cancer after breast cancer treatment. Br J Cancer 89: 840-846.
22. Zablotska LB, Chak A, Das A, Neugut AI (2005) Increased risk of squamous cell esophageal cancer after adjuvant radiation therapy for primary breast cancer. Am J Epidemiol 161: 330-337.
23. Salminen EK, Pukkala E, Kiel KD, Hakulinen TT (2006) Impact of radiotherapy in the risk of esophageal cancer as subsequent primary cancer after breast cancer. Int J Radiat Oncol Biol Phys 65: 699-704.
24. Andrieu N, Easton DF, Chang-Claude J, Rookus MA, Brohet R, Cardis E, Antoniou AC, Wagner T, Simard J, Evans G, Peock S, Fricker JP, Nogues C, Van't Veer L, Van Leeuwen FE, Goldgar DE (2006) Effect of chest X-rays on the risk of breast cancer among BRCA1/2 mutation carriers in the international BRCA1/2 carrier cohort study: a report from the EMBRACE, GENEPSO, GEO-HEBON, and IBCCS Collaborators' Group. J Clin Oncol 24: 3361-3366.
25. Schlumberger MJ (1998) Papillary and follicular thyroid carcinoma. N Engl J Med 338: 297-306.
26. Petrich T, Widjaja A, Musholt TJ, Hofmann M, Brunkhorst T, Ehrenheim C, Oetting G, Knapp WH (2001) Outcome after radioiodine therapy in 107 patients with differentiated thyroid carcinoma and initial bone metastases: side-effects and influence of age. Eur J Nucl Med 28: 203-208.
27. Berthe E, Henry-Amar M, Michels JJ, Rame JP, Berthet P, Babin E, Icard P, Samama G, Galateau-Salle F, Mahoudeau J, Bardet S (2004) Risk of second primary cancer following differentiated thyroid cancer. Eur J Nucl Med Mol Imaging 31: 685-691.
28. Chuang SC, Hashibe M, Yu GP, Le AD, Cao W, Hurwitz EL, Rao JY, Neugut AI, Zhang ZF (2006) Radiotherapy for primary thyroid cancer as a risk factor for second primary cancers. Cancer Lett 238: 42-52.
29. Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, Caillou B, Ricard M, Lumbroso JD, De Vathaire F, Schlumberger M (2006) Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 91: 2892-2899.
30. Dickman PW, Holm LE, Lundell G, Boice JD Jr, Hall P (2003) Thyroid cancer risk after thyroid examination with 131I: a population-based cohort study in Sweden. Int J Cancer 106: 580-587.
31. Ishikawa K, Noguchi S, Tanaka K, Fukuda A, Hirohata T (1996) Second primary neoplasms in thyroid cancer patients. Jpn J Cancer Res 87: 232-239.
32. Dottorini ME, Lomuscio G, Mazzucchelli L, Vignati A, Colombo L (1995) Assessment of female fertility and carcinogenesis after iodine-131 therapy for differentiated thyroid carcinoma. J Nucl Med 36: 21-27.
33. Glanzmann C (1992) Subsequent malignancies in patients treated with 131-iodine for thyroid cancer. Strahlenther Onkol 168: 337-343.
34. Canchola AJ, Horn-Ross PL, Purdie DM (2006) Risk of second primary malignancies in women with papillary thyroid cancer. Am J Epidemiol 163: 521-527.
35. Bhattacharyya N, Chien W (2006) Risk of second primary malignancy after radioactive iodine treatment for differentiated thyroid carcinoma. Ann Otol Rhinol Laryngol 115: 607-610.
36. Tsang RW, Brierley JD, Simpson WJ, Panzarella T, Gospodarowicz MK, Sutcliffe SB (1998) The effects of surgery, radioiodine, and external radiation therapy on the clinical outcome of patients with differentiated thyroid carcinoma. Cancer 82: 375-388.
37. Chow SM, Law SC, Mendenhall WM, Au SK, Yau S, Mang O, Lau WH (2004) Differentiated thyroid carcinoma in childhood and adolescence-clinical course and role of radioiodine. Pediatr Blood Cancer 42: 176-183.
38. Travis CC, Stabin MG (2006) 131I ablation treatment in young females after the Chernobyl accident. J Nucl Med 47: 1723-1727.
39. Reiners C, Lassmann M, Hanscheid H (2006) A perspective on post-Chernobyl radioablation in young females. J Nucl Med 47: 1563-1564.
40. Hod N, Hagag P, Baumer M, Sandbank J, Horne T (2005) Differentiated thyroid carcinoma in children and young adults: evaluation of response to treatment. Clin Nucl Med 30: 387-390.
41. Shapiro NL, Bhattacharyya N (2005) Population-based outcomes for pediatric thyroid carcinoma. Laryngoscope 115: 337-340.
42. Collini P, Massimino M, Leite SF, Mattavelli F, Seregni E, Zucchini N, Spreafico F, Ferrari A, Castellani MR, Cantu G, Fossati-Bellani F, Rosai J (2006) Papillary thyroid carcinoma of childhood and adolescence: a 30-year experience at the Istituto Nazionale Tumori in Milan. Pediatr Blood Cancer 46: 300-306.
43. Drozd V, Leonova T, Mitjukova T, Platonova T, Shimanskaja I, Lushchyk M, Biko J, Reiners C, Yamashita S (2007) Follow-up results in radiation-induced childhood thyroid cancer patients in Belarus. Program of the 80th general scientific assembly of the Japan Endocrine Society, Tokyo, Japan, p. 111 (Abstract).
44. Xing M, Westra WH, Tufano RP, Cohen Y, Rosenbaum E, Rhoden KJ, Carson KA, Vasko V, Larin A, Tallini G, Tolaney S, Holt EH, Hui P, Umbricht CB, Basaria S, Ewertz M, Tufaro AP, Califano JA, Ringel MD, Zeiger MA, Sidransky D, Ladenson PW (2005) BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer. J Clin Endocrinol Metab 90: 6373-6379.
45. Kumagai A, Namba H, Saenko VA, Ashizawa K, Ohtsuru A, Ito M, Ishikawa N, Sugino K, Ito K, Jeremiah S, Thomas GA, Bogdanova TI, Tronko MD, Nagayasu T, Shibata Y, Yamashita S (2004) Low frequency of BRAFT1796A mutations in childhood thyroid carcinomas. J Clin Endocrinol Metab 89: 4280-4284.
46. Lima J, Trovisco V, Soares P, Maximo V, Magalhaes J, Salvatore G, Santoro M, Bogdanova T, Tronko M, Abrosimov A, Jeremiah S, Thomas G, Williams D, Sobrinho-Simoes M (2004) BRAF mutations are not a major event in post-Chernobyl childhood thyroid carcinomas. J Clin Endocrinol Metab 89: 4267-4271.
47. Nikiforova MN, Ciampi R, Salvatore G, Santoro M, Gandhi M, Knauf JA, Thomas GA, Jeremiah S, Bogdanova TI, Tronko MD, Fagin JA, Nikiforov YE (2004) Low prevalence of BRAF mutations in radiation-induced thyroid tumors in contrast to sporadic papillary carcinomas. Cancer Lett 209: 1-6.
48. Robbins RJ, Schlumberger MJ (2005) The evolving role of (131)I for the treatment of differentiated thyroid carcinoma. J Nucl Med 46 Suppl 1: 28S-37S.
49. Cardis E, Kesminiene A, Ivanov V, Malakhova I, Shibata Y, Khrouch V, Drozdovitch V, Maceika E, Zvonova I, Vlassov O, Bouville A, Goulko G, Hoshi M, Abrosimov A, Anoshko J, Astakhova L, Chekin S, Demidchik E, Galanti R, Ito M, Korobova E, Lushnikov E, Maksioutov M, Masyakin V, Nerovnia A, Parshin V, Parshkov E, Piliptsevich N, Pinchera A, Polyakov S, Shabeka N, Suonio E, Tenet V, Tsyb A, Yamashita S, Williams D (2005) Risk of thyroid cancer after exposure to 131I in childhood. J Natl Cancer Inst 97: 724-732.
50. Reiners C, Farahati J (1999) 131I therapy of thyroid cancer patients. Q J Nucl Med 43: 324-335.
51. Dow KH, Ferrell BR, Anello C (1997) Quality-of-life changes in patients with thyroid cancer after withdrawal of thyroid hormone therapy. Thyroid 7: 613-619.
52. Meier CA, Braverman LE, Ebner SA, Veronikis I, Daniels GH, Ross DS, Deraska DJ, Davies TF, Valentine M, DeGroot LJ, et al. (1994) Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (phase I/II study). J Clin Endocrinol Metab 78: 188-196.
53. Ladenson PW, Braverman LE, Mazzaferri EL, Brucker-Davis F, Cooper DS, Garber JR, Wondisford FE, Davies TF, DeGroot LJ, Daniels GH, Ross DS, Weintraub BD (1997) Comparison of administration of recombinant human thyrotropin with withdrawal of thyroid hormone for radioactive iodine scanning in patients with thyroid carcinoma. N Engl J Med 337: 888-896.
54. Haugen BR, Pacini F, Reiners C, Schlumberger M, Ladenson PW, Sherman SI, Cooper DS, Graham KE, Braverman LE, Skarulis MC, Davies TF, DeGroot LJ, Mazzaferri EL, Daniels GH, Ross DS, Luster M, Samuels MH, Becker DV, Maxon HR, 3rd, Cavalieri RR, Spencer CA, McEllin K, Weintraub BD, Ridgway EC (1999) A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. J Clin Endocrinol Metab 84: 3877-3885.
55. Schroeder PR, Haugen BR, Pacini F, Reiners C, Schlumberger M, Sherman SI, Cooper DS, Schuff KG, Braverman LE, Skarulis MC, Davies TF, Mazzaferri EL, Daniels GH, Ross DS, Luster M, Samuels MH, Weintraub BD, Ridgway EC, Ladenson PW (2006) A comparison of short-term changes in health-related quality of life in thyroid carcinoma patients undergoing diagnostic evaluation with recombinant human thyrotropin compared with thyroid hormone withdrawal. J Clin Endocrinol Metab 91: 878-884.
56. de Keizer B, Hoekstra A, Konijnenberg MW, de Vos F, Lambert B, van Rijk PP, Lips CJ, de Klerk JM (2004) Bone marrow dosimetry and safety of high 131I activities given after recombinant human thyroid-stimulating hormone to treat metastatic differentiated thyroid cancer. J Nucl Med 45: 1549-1554.
57. Pacini F, Ladenson PW, Schlumberger M, Driedger A, Luster M, Kloos RT, Sherman S, Haugen B, Corone C, Molinaro E, Elisei R, Ceccarelli C, Pinchera A, Wahl RL, Leboulleux S, Ricard M, Yoo J, Busaidy NL, Delpassand E, Hanscheid H, Felbinger R, Lassmann M, Reiners C (2006) Radioiodine ablation of thyroid remnants after preparation with recombinant human thyrotropin in differentiated thyroid carcinoma: results of an international, randomized, controlled study. J Clin Endocrinol Metab 91: 926-932.
58. Hanscheid H, Lassmann M, Luster M, Thomas SR, Pacini F, Ceccarelli C, Ladenson PW, Wahl RL, Schlumberger M, Ricard M, Driedger A, Kloos RT, Sherman SI, Haugen BR, Carriere V, Corone C, Reiners C (2006) Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med 47: 648-654.
59. Shen DH, Kloos RT, Mazzaferri EL, Jhian SM (2001) Sodium iodide symporter in health and disease. Thyroid 11: 415-425.
60. Mandel SJ, Mandel L (2003) Radioactive iodine and the salivary glands. Thyroid 13: 265-271.
61. Caglar M, Tuncel M, Alpar R (2002) Scintigraphic evaluation of salivary gland dysfunction in patients with thyroid cancer after radioiodine treatment. Clin Nucl Med 27: 767-771.
62. Mandel SJ, Larsen PR, Seely EW, Brent GA (1990) Increased need for thyroxine during pregnancy in women with primary hypothyroidism. N Engl J Med 323: 91-96.
63. Bohuslavizki KH, Brenner W, Klutmann S, Hubner RH, Lassmann S, Feyerabend B, Luttges J, Tinnemeyer S, Clausen M, Henze E (1998) Radioprotection of salivary glands by amifostine in high-dose radioiodine therapy. J Nucl Med 39: 1237-1242.
64. Brizel DM, Wasserman TH, Henke M, Strnad V, Rudat V, Monnier A, Eschwege F, Zhang J, Russell L, Oster W, Sauer R (2000) Phase III randomized trial of amifostine as a radioprotector in head and neck cancer. J Clin Oncol 18: 3339-3345.
65. Hahn SM, Tochner Z, Krishna CM, Glass J, Wilson L, Samuni A, Sprague M, Venzon D, Glatstein E, Mitchell JB, et al. (1992) Tempol, a stable free radical, is a novel murine radiation protector. Cancer Res 52: 1750-1753.
66. Mitchell JB, DeGraff W, Kaufman D, Krishna MC, Samuni A, Finkelstein E, Ahn MS, Hahn SM, Gamson J, Russo A (1991) Inhibition of oxygen-dependent radiation-induced damage by the nitroxide superoxide dismutase mimic, tempol. Arch Biochem Biophys 289: 62-70.
67. Vitolo JM, Cotrim AP, Sowers AL, Russo A, Wellner RB, Pillemer SR, Mitchell JB, Baum BJ (2004) The stable nitroxide tempol facilitates salivary gland protection during head and neck irradiation in a mouse model. Clin Cancer Res 10: 1807-1812.
68. McDougall IR 1992 Thyroid Disease in Clinical Practice. In. Chapman & Hall, London: 215-230.
69. Sweeney D, Johnston G 2000 Side Effects of Radioiodine Therapy for Thyroid Cancer. In: Wartofsky L (ed) Thyroid Cancer: A Comprehensive Guide To Clinical Management. Humana Press, Totowa, NJ: 155-162.
70. Nakada K, Ishibashi T, Takei T, Hirata K, Shinohara K, Katoh S, Zhao S, Tamaki N, Noguchi Y, Noguchi S (2005) Does lemon candy decrease salivary gland damage after radioiodine therapy for thyroid cancer? J Nucl Med 46: 261-266.